Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection

Abstract

Aim:To compare the efficacy of ranitidine bismuth citrate plus clarithromycin (RBC–C) vs. omeprazole plus amoxycillin (OME–AMO) in the cure of Helicobacter pylori infection.Methods:In this double‐blind, multicentre, parallel‐group study 122 H. pylori‐positive patients with active duodenal ulcer or gastritis, with confirmed history of duodenal ulcer, were randomized to treatment with ranitidine bismuth citrate 400 mg b.d. plus clarithromycin 500 mg b.d. or omeprazole 20 mg b.d. plus amoxycillin 1000 mg b.d. for 14 days, followed by 14 days of ranitidine bismuth citrate 400 mg b.d. or omeprazole 20 mg once daily, respectively, to facilitate ulcer healing. Endoscopy was carried out at the start of the study and 28 days after the end of treatment. At each endoscopy four biopsies were obtained from the antrum and four biopsies from the corpus, for rapid urease test, histology and culture. H. pylori infection was defined as a positive urease test, confirmed by histology or culture. Cure of H. pylori infection was defined as negative urease test, histology or culture from both sites.Results:Per‐protocol, all‐patients‐treated and intention‐to‐treat cure rates (95% confidence interval) were, respectively, 90% (81–89%), 90% (82–89%) and 84% (74–93%) for ranitidine bismuth citrate plus clarithromycin, and 39% (27–54%), 44% (31–57%) and 41% (29–53%) for omeprazole plus amoxycillin, P < 0.00001. Both regimens were well tolerated. Eight patients were lost to follow‐up, for lack of efficacy (one patient), adverse events (three patients) or refusal of second endoscopy (four patients).Conclusion:Ranitidine bismuth citrate 400 mg b.d. with clarithromycin 500 mg b.d. is superior to omeprazole 20 mg b.d. with amoxycillin 1000 mg b.d. Ranitidine bismuth citrate with clarithromycin is the first dual therapy with high cure rates and good tolerance, and is easy to take. It may therefore prove a suitable first‐line treatment in H. pylori infection.

Ranitidine bismuth citrate, tetracycline, clarithromycin twice‐a‐day triple therapy for clarithromycin susceptible Helicobacter pylori infection

“…These results were comparable to those achieved with proton pump inhibitor triple therapies 16 . The combination of ranitidine bismuth citrate and clarithromycin appears to be more effective than a proton pump inhibitor and either amoxycillin or clarithromycin 18 . Ranitidine bismuth citrate has also been shown to be able to substitute successfully for a proton pump inhibitor in Bazzoli’s twice‐a‐day triple therapy (ranitidine bismuth citrate, metronidazole, clarithromycin instead of proton pump inhibitor, metronidazole, clarithromycin) 8 , .…”

“… 19 Head‐to‐head comparisons are needed to address whether proton pump inhibitors provide an additional increment in in vivo effectiveness compared to H 2 ‐receptor antagonists or to ranitidine bismuth citrate 3 , . 18 , 20…”

Regular review: Treatment of Helicobacter pylori infection

“…The newer regimen of 14 days' treatment with ranitidine bismuth citrate plus clarithromycin is effective and has few side effects. In randomised trials it was superior to other dual treatments 14 – 16. It is easy to take and therefore attractive for general practice.…”

High Helicobacter pylori eradication rate with a 1‐week regimen containing ranitidine bismuth citrate

“…Ranitidine bismuth citrate (Pylorid/Tritec; Glaxo Wellcome, Uxbridge, UK) in combination with the macrolide antibiotic, clarithromycin, was a significant advance in this direction, providing what is arguably the most effective of dual eradication therapies to date 9 –11 along with a simple twice daily regimen over a period of 2 weeks 10 –14 . Current trends are, however, for 1‐week triple therapy, which is thought to be likely to encourage patient compliance, thus maximizing the chances of successful eradication with a single course of treatment.…”